Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 83
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Article in English | MEDLINE | ID: mdl-38679428

ABSTRACT

Seromucinous borderline tumors (SMBT) are papillary neoplasms without invasive capabilities. Originally categorized as ovarian tumors, SMBT, being an endometriosis-related tumor, can manifest beyond the ovaries. To date, only four cases of extraovarian SMBT have been documented in literature. In this report, we present our experience with the first case of SMBT in the uterine cervix, which exhibited highly elevated CA19-9 levels. The patient, initially clinically diagnosed with cervical cancer, underwent treatment with radical hysterectomy and was later pathologically diagnosed with SMBT of the uterine cervix. While extraovarian SMBT, especially in the uterine cervix, is extremely rare, this condition should be considered in patients with cervical masses lacking pathological evidence of malignant disease but displaying elevated CA19-9 levels.

2.
Jpn J Clin Oncol ; 50(3): 333-337, 2020 Mar 09.
Article in English | MEDLINE | ID: mdl-31829421

ABSTRACT

PURPOSE: We examined the potential predictors of lymph node involvement and evaluated whether index lesion volume assessed using multiparametric magnetic resonance imaging is associated with lymph node involvement among patients with high-risk prostate cancer. METHODS: Extended pelvic lymph node dissection was used to evaluate patients with lymph node involvement. We retrospectively analyzed consecutive 102 patients with high-risk prostate cancer who underwent extended pelvic lymph node dissection at our institution between 2011 and 2017. To evaluate the index lesion volume at multiparametric magnetic resonance imaging (mrV), lesions were manually contoured on each T2-weighted axial slice in combination with diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging and integrated using image analysis software. Logistic regression analysis was performed to identify predictors of lymph node involvement. RESULTS: The median mrV was 1.4 ml (range 0-30.1 ml), and the median number of resected lymph nodes was 14 (range 7-38). Among 102 patients, 28 (28%) had lymph node involvement. Multivariate analysis identified significant predictors of lymph node involvement as follows: biopsy Gleason-grade group 5 (odds ratio = 17.2; 95% confidence interval, 2.1-299.0; P = 0.005), preoperative mrV (odds ratio = 1.14; 95% confidence interval, 1.02-1.30; P = 0.025) and percentage of positive cores with highest Gleason-grade group (odds ratio = 1.05; 95% confidence interval, 1.01-1.10; P = 0.005). Lymph node involvement was prevalent (69%) among tumors with Gleason-grade group 5 and mrV ≥3.4 ml, but was infrequently (10%) present among tumors with Gleason-grade group ≤4 and mrV <3.4 ml. CONCLUSIONS: The combination of biopsy Gleason-grade and mrV may serve as a useful tool to stratify patients according to their risk of nodal metastases.


Subject(s)
Lymph Nodes/pathology , Multiparametric Magnetic Resonance Imaging/methods , Prostatic Neoplasms/pathology , Aged , Biopsy , Humans , Lymph Node Excision , Male , Middle Aged , Multivariate Analysis , Neoplasm Grading , Odds Ratio , Prostate-Specific Antigen , Retrospective Studies
3.
Ann Surg Oncol ; 23(6): 1916-23, 2016 06.
Article in English | MEDLINE | ID: mdl-26832881

ABSTRACT

BACKGROUND: CD133 is a transmembrane protein that is proposed to be a stem cell marker of colorectal cancer (CRC); however, the correlation between CD133 expression and survival of CRC patients with liver metastasis has not been fully examined. METHODS: CD133 expression was evaluated immunohistochemically, both in primary tumors and synchronous liver metastases of 88 consecutive CRC patients, as well as recurrent lesions in the remnant liver of 27 of these 88 patients. The relationship between CD133 expression and clinicopathological characteristics, recurrence-free survival, and overall survival (OS) was analyzed. RESULTS: CD133 expression in liver metastases (mCD133) was detected in 50 of 88 patients (56.8 %), and had significant correlation with CD133 expression in primary lesions (pCD133) (p < 0.001). CD133 expression in liver recurrent lesions (recCD133) also had a significant correlation with mCD133 (p < 0.001). mCD133+ patients had significantly longer disease-free survival (p = 0.043) and OS (p = 0.014) than mCD133- patients. In addition, mCD133+ patients had a significantly lower rate of extrahepatic recurrence (p < 0.001). CONCLUSIONS: Patients without CD133 expression in liver metastasis had significantly shorter survival, perhaps because mCD133- patients had a significantly higher rate of extrahepatic recurrence.


Subject(s)
AC133 Antigen/metabolism , Biomarkers, Tumor/metabolism , Colorectal Neoplasms/mortality , Liver Neoplasms/mortality , Neoplasm Recurrence, Local/mortality , Neoplasms, Multiple Primary/mortality , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Colorectal Neoplasms/surgery , Follow-Up Studies , Humans , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Neoplasms, Multiple Primary/metabolism , Neoplasms, Multiple Primary/secondary , Neoplasms, Multiple Primary/surgery , Prognosis , Survival Rate
4.
BMC Gastroenterol ; 16(1): 119, 2016 Oct 04.
Article in English | MEDLINE | ID: mdl-27716077

ABSTRACT

BACKGROUND: Helicobacter pylori (H. pylori) infection and eradication therapy have been known to influence gastric ghrelin and leptin secretion, which may lead to weight gain. However, the exact relationship between plasma ghrelin/leptin levels and H. pylori infection has remained controversial. The aim of this study was to investigate plasma ghrelin and leptin levels in H. pylori-positive and -negative patients, to compare the two levels of the hormones before and after H. pylori eradication, and to examine the correlation between body mass index (BMI) and active ghrelin or leptin levels, as well as that between atrophic pattern and active ghrelin or leptin levels. METHODS: Seventy-two H. pylori-positive patients who underwent upper gastrointestinal endoscopy, 46 diagnosed as having peptic ulcer and 26 as atrophic gastritis, were enrolled. Control samples were obtained from 15 healthy H. pylori-negative volunteers. The extent of atrophic change of the gastric mucosa was assessed endoscopically. Body weight was measured and blood was collected before and 12 weeks after H. pylori eradication therapy. Blood samples were taken between 8 and 10 AM after an overnight fast. RESULTS: Plasma ghrelin levels were significantly lower in H. pylori-positive patients than in H. pylori-negative patients. In particular, plasma active ghrelin levels were significantly lower in patients with gastritis compared with patients with peptic ulcer. Plasma ghrelin levels decreased after H. pylori eradication in both peptic ulcer and gastritis patients, while plasma leptin levels increased only in peptic ulcer patients. Plasma leptin levels and BMI were positively correlated, and active ghrelin levels and atrophic pattern were weakly negatively correlated in peptic ulcer patients. CONCLUSION: H. pylori infection and eradication therapy may affect circulating ghrelin/leptin levels. This finding suggests a relationship between gastric mucosal injury induced by H. pylori infection and changes in plasma ghrelin and leptin levels.


Subject(s)
Gastritis, Atrophic/blood , Ghrelin/blood , Helicobacter Infections/blood , Helicobacter pylori , Leptin/blood , Peptic Ulcer/blood , Adult , Aged , Amoxicillin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Anti-Ulcer Agents/administration & dosage , Biopsy , Body Mass Index , Body Weight/drug effects , Case-Control Studies , Clarithromycin/administration & dosage , Drug Therapy, Combination , Endoscopy, Digestive System , Female , Gastric Mucosa/pathology , Gastritis, Atrophic/microbiology , Helicobacter Infections/complications , Helicobacter Infections/drug therapy , Humans , Lansoprazole/administration & dosage , Male , Middle Aged , Peptic Ulcer/microbiology
5.
Int J Colorectal Dis ; 31(7): 1315-21, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27240821

ABSTRACT

PURPOSE: We aimed to clarify the prognostic impact of lateral pelvic lymph node (LPN) dissection (LPND) for rectal cancer through a multicenter retrospective study using propensity score analysis. METHODS: A total of 1238 patients with pathological T2-4, M0 rectal cancer who had undergone curative operation between 2007 and 2008 were examined. Majority of the patients (96 %) were treated without preoperative chemoradiotherapy (CRT). Clinical background data of the patients treated with LPND and those treated without LPND were matched using propensity scores, and hazard ratios (HRs) for cancer-specific mortality were compared. RESULTS: LPND was performed more frequently for lower rectal cancers and in patients with more advanced disease, and 29 % of the patients were treated with LPND. After matching background features by propensity scores, LPND did not correlate with improved cancer-specific survival (CSS) among the entire study population [HR, 0.73; 95 % confidence interval (CI) 0.41-1.31; P = 0.28]; however, LPND was correlated with significantly improved CSS in female patients (HR, 0.23; 95 % CI, 0.06-0.89; P = 0.04) but not in male patients (HR, 0.95; 95 % CI, 0.48-1.89; P = 0.89). The results were similar when patients treated with LPND finally diagnosed as pathologically negative for LPN metastasis were compared with those curatively treated without LPND. CONCLUSIONS: It is suggested that the prognostic impact of LPND for rectal cancer treated without CRT might be different between sexes, and LPND should be considered for female rectal cancer patients although they are diagnosed as clinically negative for LPN metastasis.


Subject(s)
Chemoradiotherapy , Lymph Node Excision , Pelvis/surgery , Preoperative Care , Propensity Score , Rectal Neoplasms/therapy , Colorectal Neoplasms/mortality , Female , Humans , Male , Middle Aged , Proportional Hazards Models , Rectal Neoplasms/mortality , Rectal Neoplasms/surgery , Retrospective Studies , Survival Analysis
6.
Int J Colorectal Dis ; 31(6): 1149-55, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27023629

ABSTRACT

PURPOSE: Colon cancers in male and female patients are suggested to be oncologically different. The aim of this study is to elucidate the prognostic impact of lymph node dissection (LND) in male and female colon cancer patients. METHODS: A total of 5941 stage I-III colon cancer patients who were curatively operated on during the period from 1997 to 2007 were retrospectively studied. Cancer-specific survival (CSS) was individually compared between for male and female patients treated with D3, D2, and D1 LND. Background differences of the patients were matched using propensity scores. RESULTS: D3, D2, and D1 LND were performed in 3756 (63 %), 1707 (29 %), and 478 (8 %), respectively, and more extensive LND was indicated for younger patients and more advanced disease. D2 LND was significantly associated with decreased cancer-specific mortality compared to D1 LND in male patients (HR 0.54, 95 % CI 0.32-0.89, p = 0.04), but not in female patients. D3 LND did not correlate to an improved prognosis compared to D2 LND both in male and female patients. CONCLUSIONS: D2 LND was associated with an improved CSS in male, but not female colon cancer patients, compared to D1 LND. This suggested that colon cancer in male and female patients might be oncologically different, and that the prognostic impact of the extent of surgical intervention for colon cancer might therefore be different between sexes.


Subject(s)
Colonic Neoplasms/surgery , Lymph Node Excision/methods , Propensity Score , Aged , Colonic Neoplasms/mortality , Disease-Free Survival , Female , Humans , Male , Multivariate Analysis , Prognosis , Proportional Hazards Models , Retrospective Studies
7.
World J Surg Oncol ; 14: 75, 2016 Mar 09.
Article in English | MEDLINE | ID: mdl-26960982

ABSTRACT

BACKGROUND: The incidence of neoplasia after surgery has not been sufficiently evaluated in patients with ulcerative colitis (UC), particularly in the Japanese population, and it is not clear whether surveillance endoscopy is effective in detecting dysplasia/cancer in the remnant rectum or pouch. The aims of this study were to assess and compare postoperative development of dysplasia/cancer in patients with UC who underwent ileorectal anastomosis (IRA) or ileal pouch-anal anastomosis (IPAA) and to evaluate the effectiveness of postoperative surveillance endoscopy. METHODS: One hundred twenty patients who received postoperative surveillance endoscopy were retrospectively reviewed for development of dysplasia/cancer in the remnant rectal mucosa or pouch. RESULTS: Three hundred seventy-nine endoscopy sessions were conducted for 30 patients after IRA, while 548 pouch endoscopy sessions were conducted for 90 patients after IPAA. In the IRA group, 5 patients developed dysplasia/cancer during postoperative surveillance and in all cases, neoplasia was detected at an early stage. In the IRA group, no patient developed neoplasia within 10 years of diagnosis; the cumulative incidence of neoplasia after disease onset was 7.2, 12.0, and 23.9% at 15, 20, and 25 years, respectively. In one case after stapled IPAA, dysplasia was found at the ileal pouch; a subsequent 9 endoscopy sessions in 8 years did not detect any dysplasia. Neoplasia was found more frequently during postoperative surveillance in the IRA group than in the IPAA group (p = .0028). The cumulative incidence of neoplasia after IRA was 3.8, 8.7, and 21.7% at 10, 15, and 20 years, respectively, and that after IPAA was 1.6% at 20 years. CONCLUSIONS: The cumulative incidence of neoplasia after IPAA was minimal. Those who underwent IRA had a greater risk of developing neoplasia than those who underwent IPAA, although postoperative surveillance endoscopy was able to detect dysplasia/cancer at an early stage. IRA can be the surgical procedure of choice only in selected cases in which it would be of benefit to the patient, with more careful surveillance.


Subject(s)
Anastomosis, Surgical/adverse effects , Colitis, Ulcerative/surgery , Endoscopy/methods , Ileum/surgery , Neoplasms/epidemiology , Proctocolectomy, Restorative/adverse effects , Rectum/surgery , Adult , Aged , Female , Follow-Up Studies , Humans , Incidence , Japan/epidemiology , Male , Middle Aged , Neoplasm Staging , Postoperative Care , Prognosis , Retrospective Studies , Young Adult
8.
World J Surg Oncol ; 14: 107, 2016 Apr 14.
Article in English | MEDLINE | ID: mdl-27080037

ABSTRACT

BACKGROUND: Clinical studies of intraperitoneal chemotherapy with paclitaxel in patients of gastric cancer with peritoneal carcinomatosis is well tolerated and effective, and rare cases of metastasis and recurrence have experienced during the treatment. Disseminated carcinomatosis of the bone marrow is highly rare in gastric cancer and associated with a poor prognosis. CASE PRESENTATION: A 59-year-old woman of gastric cancer with peritoneal carcinomatosis received five courses of chemotherapy with intraperitoneal administration of paclitaxel, and laparoscopy showed disappearance of the peritoneal carcinomatosis. She subsequently underwent total gastrectomy, and the histopathological findings showed a complete response to the chemotherapy. Postoperatively, chemotherapy with intraperitoneal administration of paclitaxel was continued for 30 months, without apparent recurrence. However, the gastric cancer recurred as disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation, and we hence changed the chemotherapy regimen to weekly irinotecan. Remission was achieved, and she did not experience any major symptoms; however, she died 6 months after the diagnosis of disseminated carcinomatosis of the bone marrow. CONCLUSIONS: Since intraperitoneal paclitaxel administration can strongly suppress peritoneal carcinomatosis of gastric cancer, careful attention should be paid not only to peritoneal recurrence but also for rare site metastases, such as bone marrow metastases.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Marrow Neoplasms/etiology , Gastrectomy/adverse effects , Neoplasm Recurrence, Local/therapy , Peritoneal Neoplasms/etiology , Stomach Neoplasms/therapy , Bone Marrow Neoplasms/pathology , Combined Modality Therapy , Disseminated Intravascular Coagulation , Female , Humans , Injections, Intraperitoneal , Middle Aged , Neoplasm Recurrence, Local/pathology , Peritoneal Neoplasms/pathology , Prognosis , Stomach Neoplasms/pathology , Time Factors
9.
Surg Today ; 46(10): 1115-22, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26676416

ABSTRACT

Gastrointestinal (GI) cancer, including gastric and colorectal cancer, is a major cause of death worldwide. A substantial proportion of patients with GI cancer have a familial history, and several causative genes have been identified. Gene carriers with these hereditary GI syndromes often harbor several kinds of cancer at an early age, and genetic testing and specific surveillance may save their lives through early detection. Gastroenterologists and GI surgeons should be familiar with these syndromes, even though they are not always associated with a high penetrance of GI cancer. In this review, we provide an overview and discuss the diagnosis, genetic testing, and management of four major hereditary GI cancers: familial adenomatous polyposis, Lynch syndrome, hereditary diffuse gastric cancer, and Li-Fraumeni syndrome.


Subject(s)
Adenomatous Polyposis Coli/genetics , Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , Li-Fraumeni Syndrome/genetics , Stomach Neoplasms/genetics , Adenomatous Polyposis Coli Protein/genetics , Antigens, CD , Cadherins/genetics , Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis , Colorectal Neoplasms, Hereditary Nonpolyposis/prevention & control , Colorectal Neoplasms, Hereditary Nonpolyposis/therapy , Genetic Testing , Humans , Li-Fraumeni Syndrome/diagnosis , Li-Fraumeni Syndrome/prevention & control , Li-Fraumeni Syndrome/therapy , MutL Protein Homolog 1/genetics , MutS Homolog 2 Protein/genetics , Mutation , Stomach Neoplasms/diagnosis , Stomach Neoplasms/prevention & control , Stomach Neoplasms/therapy , Tumor Suppressor Protein p53/genetics
10.
Dig Endosc ; 28(3): 260-5, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26096182

ABSTRACT

Long-standing ulcerative colitis patients are known to be at high risk for the development of colorectal cancer. Therefore, surveillance colonoscopy has been recommended for these patients. Because colitis-associated colorectal cancer may be difficult to identify even by colonoscopy, a random biopsy method has been recommended. However, the procedure of carrying out a random biopsy is tedious and its effectiveness has also not yet been demonstrated. Instead, targeted biopsy with chromoendoscopy has gained popularity in European and Asian countries. Chromoendoscopy is generally considered to be an effective tool for ulcerative colitis surveillance and is recommended in the guidelines of the British Society of Gastroenterology and the European Crohn's and Colitis Organisation. Although image-enhanced endoscopy, such as narrow-band imaging and autofluorescence imaging, has been investigated as a potential ulcerative colitis surveillance tool, it is not routinely applied for ulcerative colitis surveillance in its present form. The appropriate intervals of surveillance colonoscopy have yet to be determined. Although the Japanese and American guidelines recommend annual or biannual colonoscopy, the British Society of Gastroenterology and the European Crohn's and Colitis Organisation stratified their guidelines according to the risks of colorectal cancer. A randomized controlled trial comparing random and targeted biopsy methods has been conducted in Japan and although the final analysis is still ongoing, the results of this study should address this issue. In the present review, we focus on the current detection methods and characterization of dysplasia/cancer and discuss the appropriate intervals of colonoscopy according to the stratified risks.


Subject(s)
Colitis, Ulcerative/complications , Colitis, Ulcerative/pathology , Colonoscopy , Colorectal Neoplasms/diagnosis , Population Surveillance , Biopsy , Colorectal Neoplasms/etiology , Early Detection of Cancer , Humans
11.
Ann Surg Oncol ; 22 Suppl 3: S621-9, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26350364

ABSTRACT

BACKGROUND: This study aimed to clarify differences in prognostic factors, metastatic features, and recurrence rates between histologic types in patients with stage 4 colorectal cancer (CRC) who had undergone curative resection. METHODS: The data from 1131 patients with stage 4 colorectal cancer from the databases of referral institutions were analyzed. The patients were divided into two groups according to histologic types as follows: patients with poorly differentiated adenocarcinoma, mucinous adenocarcinoma, or signet-ring cell carcinoma (Por/Muc/Sig) and patients with well-differentiated or moderately differentiated adenocarcinoma (Wel/Mod). Differences in clinicopathologic features, relapse-free survival (RFS) rates, and cancer-specific survival (CSS) rates between the groups were evaluated. RESULTS: Although RFS did not differ between the Por/Muc/Sig and Wel/Mod groups, CSS was significantly shorter in the Por/Muc/Sig group's than in the Wel/Mod group, and survival after recurrence was significantly worse in the Por/Muc/Sig group than in theWel/Mod group. The incidence of peritoneal or local recurrence was significantly higher for the Por/Muc/Sig patients, whereas the resection recurrence rate was 16.4 %. Multivariate analysis suggested that histologic type was an independent prognostic factor for survival after recurrence. CONCLUSIONS: The patients with Por/Muc/Sig CRC synchronous metastasis had significantly shorter survival times than the patients with other CRC histologies, even if the metastases were curatively resected.


Subject(s)
Adenocarcinoma, Mucinous/secondary , Adenocarcinoma/secondary , Carcinoma, Signet Ring Cell/secondary , Colorectal Neoplasms/pathology , Neoplasm Recurrence, Local/pathology , Peritoneal Neoplasms/secondary , Adenocarcinoma/surgery , Adenocarcinoma, Mucinous/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Signet Ring Cell/surgery , Colorectal Neoplasms/surgery , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Recurrence, Local/surgery , Neoplasm Staging , Peritoneal Neoplasms/surgery , Prognosis , Retrospective Studies , Survival Rate , Young Adult
12.
Ann Surg Oncol ; 22(5): 1513-9, 2015 May.
Article in English | MEDLINE | ID: mdl-25398278

ABSTRACT

BACKGROUND: The lymph node ratio (LNR) was proposed as a prognostic indicator in Stage III colorectal cancer (CRC) patients in recent studies. The purpose of this study was to evaluate the prognostic impact of the LNR in Stage IV CRC patients who have undergone curative resection. METHODS: A retrospective review of 119 Stage IV CRC patients who underwent curative resection in our institute from 1997 to 2009 was performed. Patients were divided into two groups (low LNR and high LNR) by means of their median LNR. A disease-free survival (DFS) and an overall survival (OS) were analyzed using the Kaplan-Meier curve; multivariate analysis was performed using the Cox proportional hazard model. RESULTS: The cutoff value for the LNR was 0.111. For the entire study group, the 5-year DFS was 22 % and the 5-year OS was 65 %. DFS was not significantly different between patients in the low LNR group and the high LNR group (25 and 19 %, respectively; P = 0.317), but OS was significantly higher in the low LNR group patients compared with the high LNR group patients (77 and 54 %, respectively; P < 0.001). Using multivariate analysis, we identified the LNR as an independent prognostic factor for OS, with a hazard ratio of 3.08 (95 % CI 1.38-8.19; P = 0.005). CONCLUSIONS: LNR is a potent prognostic indicator for stratification in Stage IV CRC patients who have undergone curative resection.


Subject(s)
Adenocarcinoma/secondary , Colorectal Neoplasms/pathology , Liver Neoplasms/secondary , Lymph Nodes/pathology , Neoplasm Recurrence, Local/pathology , Adenocarcinoma/mortality , Adenocarcinoma/surgery , Colorectal Neoplasms/mortality , Colorectal Neoplasms/surgery , Female , Follow-Up Studies , Humans , Liver Neoplasms/mortality , Liver Neoplasms/surgery , Lymphatic Metastasis , Male , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/surgery , Neoplasm Staging , Prognosis , Proportional Hazards Models , Retrospective Studies , Survival Rate
13.
BMC Gastroenterol ; 15: 100, 2015 Aug 11.
Article in English | MEDLINE | ID: mdl-26261039

ABSTRACT

BACKGROUND: Obesity has become one of the most serious social problems in developed countries, including Japan. The relationship between the gut microbiota and obesity has recently attracted the attention of many researchers. Although the gut microbiota was long thought to contribute to obesity, the exact association remains largely unknown. We examined the human gut microbiota composition in a Japanese population in order to determine its relationship to obesity. METHODS: Stool samples from 23 non-obese subjects (body mass index [BMI] <20 kg/m(2)) and 33 obese subjects (BMI ≥25 kg/m(2)) were collected and DNA was extracted prior to colonoscopy. After terminal restriction fragment length polymorphism (T-RFLP) analysis, samples from 10 subjects (4 non-obese and 6 obese) were selected and subjected to next-generation sequencing for species-level analysis. RESULTS: T-RFLP analysis showed significantly reduced numbers of Bacteroidetes and a higher Firmicutes to Bacteroidetes ratio in obese subjects compared with non-obese subjects. Bacterial diversity was significantly greater in obese subjects compared with non-obese subjects. Next-generation sequencing revealed that obese and non-obese subjects had different gut microbiota compositions and that certain bacterial species were significantly associated with each group (obese: Blautia hydrogenotorophica, Coprococcus catus, Eubacterium ventriosum, Ruminococcus bromii, Ruminococcus obeum; non-obese: Bacteroides faecichinchillae, Bacteroides thetaiotaomicron, Blautia wexlerae, Clostridium bolteae, Flavonifractor plautii). CONCLUSION: Gut microbial properties differ between obese and non-obese subjects in Japan, suggesting that gut microbiota composition is related to obesity.


Subject(s)
Gastrointestinal Microbiome/genetics , Gastrointestinal Tract/microbiology , Obesity/microbiology , Polymorphism, Restriction Fragment Length , Adult , Asian People , Bacteroidetes/genetics , Bacteroidetes/isolation & purification , Body Mass Index , DNA, Bacterial/analysis , Feces/microbiology , Female , Firmicutes/genetics , Firmicutes/isolation & purification , Humans , Japan , Male , Middle Aged , Sequence Analysis, DNA/methods
14.
Int J Colorectal Dis ; 30(6): 807-12, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25922146

ABSTRACT

PURPOSE: Retrospective studies have shown that primary tumor resection improves the prognosis of patients with colorectal cancer (CRC) with unresectable metastasis (mCRC). The aim of this study was to investigate the prognostic impact of primary tumor resection in various subgroups of mCRC patients. METHODS: A total of 1982 patients with mCRC from January 1997 to December 2007 were retrospectively evaluated. The impact of primary tumor resection on cancer-specific survival (CSS) was analyzed using propensity score analysis to mitigate selection bias. Covariates in the models for propensity scores included treatment period, age, gender, tumor location, depth, lymph node metastasis, number of metastatic organs, and carcinoembryonic antigen (CEA) levels. RESULTS: Among the whole patient population, primary tumor resection significantly improved CSS [hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.32-0.66, p < 0.01]. However, primary tumor resection did not significantly improve CSS in the following subgroups: patients treated in the first 5 years of the study (HR 0.56, 95% CI 0.28-1.13, p = 0.08), patients aged >65 years (HR 0.72, 95% CI 0.36-1.42, p = 0.31), female patients (HR 0.60, 95% CI 0.31-1.17, p = 0.13), patients with right-sided colon cancer (HR 0.68, 95% CI 0.39-1.20, p = 0.17), and patients without nodal involvement (HR 0.54, 95% CI 0.25-1.17, p = 0.09). CONCLUSIONS: Our study suggests that primary tumor resection improves the survival of patients with mCRC. However, the prognostic benefit is different among patient subpopulations.


Subject(s)
Colorectal Neoplasms/pathology , Colorectal Neoplasms/surgery , Age Factors , Aged , Biomarkers, Tumor/blood , Carcinoembryonic Antigen/blood , Colorectal Neoplasms/mortality , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Propensity Score , Proportional Hazards Models , Retrospective Studies , Sex Factors
15.
Int J Colorectal Dis ; 30(9): 1165-71, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26049902

ABSTRACT

PURPOSE: The platelet to lymphocyte ratio (PLR) is a potential prognostic marker in a number of different cancers. The aim of this study was to evaluate the prognostic impact of the PLR in patients with stage II colorectal cancer (CRC) who have undergone curative resection but not adjuvant chemotherapy. METHODS: A retrospective review was performed on 234 patients with stage II CRC who underwent curative resection, but not adjuvant chemotherapy, in our institute. The patients were divided into low and high PLR groups, and patient survival as well as several clinicopathological factors were compared between the groups. Disease-free survival (DFS) and cancer-specific survival (CSS) were analyzed by using the Kaplan-Meier method, and multivariate analysis was performed by using the Cox proportional hazard model. RESULTS: The cutoff value of the PLR determined by using a receiver-operating characteristic curve analysis was 25.4. DFS and CSS were significantly better in patients with a low PLR compared to patients with a high PLR (P = 0.002 and P = 0.011, respectively). On multivariate analysis, we identified the PLR as an independent prognostic factor for DFS and CSS, with a hazard ratio of 2.65 (95 % confidence interval [CI], 1.26-5.45; P = 0.011) and 3.61 (95 % CI, 1.08-12.64; P = 0.038, respectively). CONCLUSIONS: The PLR is a good prognostic indicator in patients with stage II CRC who have undergone curative surgery but not adjuvant chemotherapy.


Subject(s)
Adenocarcinoma/pathology , Adenocarcinoma/surgery , Colorectal Neoplasms/pathology , Colorectal Neoplasms/surgery , Neoplasm Recurrence, Local/blood , Adenocarcinoma/blood , Aged , Area Under Curve , Blood Vessels/pathology , Colorectal Neoplasms/blood , Disease-Free Survival , Female , Humans , Lymphatic Vessels/pathology , Lymphocyte Count , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Platelet Count , Predictive Value of Tests , Preoperative Period , ROC Curve , Retrospective Studies , Survival Rate
16.
Int J Clin Oncol ; 20(4): 633-40, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26059248

ABSTRACT

Robotic technology, which has recently been introduced to the field of surgery, is expected to be useful, particularly in treating rectal cancer where precise manipulation is necessary in the confined pelvic cavity. Robotic surgery overcomes the technical drawbacks inherent to laparoscopic surgery for rectal cancer through the use of multi-articulated flexible tools, three-dimensional stable camera platforms, tremor filtering and motion scaling functions, and greater ergonomic and intuitive device manipulation. Assessments of the feasibility and safety of robotic surgery for rectal cancer have reported similar operation times, blood loss during surgery, rates of postoperative morbidity, and circumferential resection margin involvement when compared with laparoscopic surgery. Furthermore, rates of conversion to open surgery are reportedly lower with increased urinary and male sexual functions in the early postoperative period compared with laparoscopic surgery, demonstrating the technical advantages of robotic surgery for rectal cancer. However, long-term outcomes and the cost-effectiveness of robotic surgery for rectal cancer have not been fully evaluated yet; therefore, large-scale clinical studies are required to evaluate the efficacy of this new technology.


Subject(s)
Rectal Neoplasms/surgery , Robotic Surgical Procedures , Blood Loss, Surgical , Clinical Trials as Topic , Conversion to Open Surgery , Endoscopy/adverse effects , Endoscopy/methods , Humans , Learning Curve , Robotic Surgical Procedures/adverse effects , Robotic Surgical Procedures/economics , Robotic Surgical Procedures/methods
17.
World J Surg Oncol ; 13: 180, 2015 May 12.
Article in English | MEDLINE | ID: mdl-25962419

ABSTRACT

BACKGROUND: Alpha-fetoprotein (AFP)-producing rectal cancer is very rare, and this type of cancer frequently metastasizes to the liver with a poor prognosis. To date, only 11 cases of AFP-producing colorectal cancer have been reported. CASE PRESENTATION: A 41-year-old woman was first presented to the hospital for anal bleeding. An elevated tumor with a central shallow depression in the lower rectum was detected by colonoscopy. Transanal excision was performed, and the histology revealed adenocarcinoma. Further immunohistopathological examination revealed that the tumor was an AFP-producing adenocarcinoma of the rectum. Although local resection was performed 2 months before the diagnosis of AFP tumor, the serum AFP level was normal. The depth of the submucosal invasion was 5,000 µm, and there was venous invasion. Also, no lymphatic invasion was detected. Therefore, additional surgical resection with lymph node dissection was conducted, and the patient underwent laparoscopic intersphincteric resection. No residual cancer was identified in the surgical specimens, and there was no evidence of lymph node metastasis. The patient was discharged 18 days postoperatively, and 12 months after the operation, there are no signs of recurrence. CONCLUSION: To the best of our knowledge, this is the first case of an AFP-producing rectal cancer that was diagnosed at an early stage.


Subject(s)
Adenocarcinoma/metabolism , Biomarkers, Tumor/metabolism , Rectal Neoplasms/metabolism , alpha-Fetoproteins/metabolism , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adult , Female , Humans , Immunoenzyme Techniques , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Rectal Neoplasms/pathology , Rectal Neoplasms/surgery
18.
Hepatogastroenterology ; 62(140): 853-8, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26902015

ABSTRACT

BACKGROUND/AIMS: Despite recent advances in medical therapy, the role of surgery for severe ulcerative colitis remains important and determining the timing and indications for colectomy are difficult for both gastroenterologists and surgeons. We compared the clinical characteristics and postoperative complications of emergency surgeries for ulcerative colitis to those of elective surgeries. METHODOLOGY: We retrospectively examined 77 patients with ulcerative colitis who underwent colectomy without cancer or dysplasia in our institute in 1989-2012. Clinicopathological features, cytomegalovirus involvement, and postoperative complications were evaluated. RESULTS: Twenty-seven patients underwent emergency surgeries and the other 50 underwent elective surgeries. Emergency surgeries were performed significantly earlier in the disease course than elective surgeries. Postoperative complications were more frequent in emergency surgeries than in elective surgeries. Those who underwent emergency surgeries with relative indications tended to develop postoperative complications more frequently when intensive long-term steroid therapy was introduced. CONCLUSIONS: Emergency surgeries were associated with frequent postoperative complications. For refractory severe ulcerative colitis, cytomegalovirus involvement should be determined and prolonged steroid therapy is associated with postoperative complications; therefore, early treatment decisions are important.


Subject(s)
Colectomy , Colitis, Ulcerative/surgery , Cytomegalovirus Infections/epidemiology , Emergencies , Ileus/epidemiology , Pneumonia/epidemiology , Postoperative Complications/epidemiology , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Case-Control Studies , Child , Cohort Studies , Colitis, Ulcerative/drug therapy , Elective Surgical Procedures , Female , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Surgical Wound Infection/epidemiology , Young Adult
19.
Surg Today ; 45(9): 1073-81, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25373362

ABSTRACT

PURPOSE: The significance of peritoneal lavage cytology as a prognostic marker has been examined in various types of cancer. However, the meaning of positive peritoneal lavage cytology in colorectal cancer is still controversial. The aim of this review is to evaluate the prognostic significance of positive peritoneal lavage cytology in colorectal cancer. METHODS: An English literature search was performed on all studies published between 1998 and 2014 that compared the detection of peritoneal free cancer cells with survival or recurrence. RESULTS: Eighteen articles met the inclusion criteria. All studies employed one (or more) of the three techniques used to detect free cancer cells in the peritoneal cavity: (1) conventional cytology, (2) immunocytochemistry or (3) polymerase chain reaction. The incidence of positive peritoneal lavage cytology ranged from 2.2 to 47.2% across the studies. The factors correlated with positive peritoneal lavage cytology were tumor penetration and metastases (lymph node, liver and peritoneum). In nine studies, positive lavage findings were associated with a worse survival, and it was associated with increased recurrence in 13 studies. CONCLUSION: Positive peritoneal lavage cytology seems to be an indicator of a poor prognosis in colorectal cancer patients. Further studies are needed to clarify the prognostic impact of peritoneal lavage cytology, by comparing the different methods used for the collection of the peritoneal lavage.


Subject(s)
Colorectal Neoplasms/diagnosis , Cytodiagnosis/methods , Cytodiagnosis/statistics & numerical data , Peritoneal Lavage/methods , Peritoneal Lavage/statistics & numerical data , Colorectal Neoplasms/mortality , Humans , Incidence , Neoplasm Recurrence, Local , Prognosis , Specimen Handling/methods , Survival Rate
20.
Surg Today ; 45(8): 933-8, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25346254

ABSTRACT

Despite the development of new therapies, including anti-TNF alpha antibodies and immunosuppressants, a substantial proportion of patients with ulcerative colitis (UC) still require surgery. Restorative proctocolectomy with ileal-pouch anal anastomosis is the standard surgical treatment of choice for UC. With the advent of laparoscopic techniques for colorectal surgery, ileal-pouch anal anastomosis has also been performed laparoscopically. This paper reviews the history and current trends in laparoscopic surgery for UC. The accumulation of experience and improvement of laparoscopic devices have shifted the paradigm of UC surgery towards laparoscopic surgery over the past decade. Although laparoscopic surgery requires a longer operation, it provides significantly better short and long-term outcomes. The short-term benefits of laparoscopic surgery over open surgery include shorter hospital stays and fasting times, as well as better cosmesis. The long-term benefits of laparoscopy include better fecundity in young females. Some surgeons favor laparoscopic surgery even for severe acute colitis. More efforts are being made to develop newer laparoscopic methods, such as reduced port surgery, including single incision laparoscopic surgery and robotic surgery.


Subject(s)
Colitis, Ulcerative/surgery , Laparoscopy/methods , Laparoscopy/trends , Proctocolectomy, Restorative/methods , Proctocolectomy, Restorative/trends , Anal Canal/surgery , Anastomosis, Surgical , Colonic Pouches , Female , Humans , Laparoscopy/instrumentation , Length of Stay , Male , Proctocolectomy, Restorative/instrumentation , Robotic Surgical Procedures/trends , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL